Overview of Trophicreme

Property	Description
Active Ingredient	Estriol (Oestriol)
Form	Crème vaginale (Vaginal Cream)
Pharmacological Class	Estrogen (Estrogènes)
Common Use	Targeted hormonal support for local tissue changes
Origin	Naturally occurring, bioidentical estrogen

What Type of Medicine is Trophicreme?

Trophicreme is a prescription-only medication classified as an estrogen (estrogènes) product, formulated as a crème vaginale (vaginal cream) for local treatment. It is grouped within the Menopausal Hormone Therapy (THS) category, identified by the Anatomical Therapeutic Chemical (ATC) code G03CA04.

This medication is distinguished by its intended use for localized action via the vaginal route. Vaginal application of estriol is associated with very low systemic bioavailability. This low absorption profile ensures that the therapeutic effect is concentrated on the target tissues, defining Trophicreme as a specialized, single-ingredient product.

Composition and Origin: Is Estriol a Natural Hormone?

The sole active ingredient in Trophicreme is Estriol (also known as Oestriol or E3), which is a naturally occurring estrogen hormone. This chemical structure classifies Estriol as a bioidentical estrogen hormone, meaning it is structurally identical to a hormone produced naturally in the body. Estriol’s low intrinsic potency makes it highly suitable for its role in specific local treatment.

The finished medicine is an aqueous-based cream base (topical preparation) designed for direct mucosal application using a specific applicateur doseur. This formulation facilitates effective contact between the active substance and the target tissue, ensuring optimal local action.

Trophicreme’s General Purpose

Trophicreme’s general purpose is to provide targeted hormonal support to estrogen-dependent tissues that have undergone functional changes in postmenopausal patients. The medication functions as an Estrogen Receptor Agonist, meaning the Estriol activates specific receptors on the cells to initiate the necessary estrogenic action. This mechanism helps to restore and maintain the health and function of tissues that arise from the body's natural decline in estrogen levels.

What side effects are possible with Trophicreme?

Possible Side Effects and Safety Information

The safety profile for Estriol vaginal cream is structured by regulatory authorities to address both local adverse reactions and the systemic risks associated with the larger estrogen class of medicines. Due to the product's very low systemic absorption, most documented side effects are localized.

Adverse Reactions Listed in Official Documents

Adverse reactions are formally classified by their frequency. Common effects are generally related to the site of application and may include vaginal irritation, itching, increased vaginal discharge, and localized discomfort. Other common effects listed in regulatory documents include headache and breast tenderness. Some effects, such as abnormal vaginal spotting or bleeding, are also documented but may be classified as having a not known frequency.

Systemic Safety and Estrogen Class Risks

As a member of the estrogen class, the medicine's labeling includes the serious adverse reactions associated with systemic Hormone Replacement Therapy (HRT), although these risks apply to a lesser extent for low-dose, local preparations. These serious documented risks include the possibility of increased risk for Venous Thromboembolism (VTE), stroke, and endometrial cancer (for women with an intact uterus using unopposed estrogen).

Safety Constraints and Considerations

Regulatory documents establish strict limitations on use. The medicine is formally contraindicated (prohibited) in individuals with a known or history of breast cancer, known or suspected estrogen-dependent malignant tumors, current or past venous thromboembolism, and undiagnosed abnormal genital bleeding. Furthermore, the labeling notes that local irritation may be more noticeable at the start of treatment and often resolves after the initial weeks of use. Official safety notes also address special populations, noting that estrogen use may decrease the quality and quantity of breast milk.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented descriptions of overdose for estriol-containing products and the regulator-mandated emergency actions.

Documented Clinical Manifestations

Acute overdosage of estrogen products is not known to generally result in severe toxicities. However, an overdose may present with clinical signs related to an excess of estrogenic activity, including:

Gastrointestinal: Nausea, vomiting, abdominal cramps, and bloating.
Reproductive: Breast tenderness or pain, and breakthrough vaginal bleeding (which may occur several days after the exposure).
Systemic: Headache and unusual tiredness or weakness.

Emergency Action Required

If an overdose of Trophicreme is suspected, immediate medical attention must be sought. Regulatory guidance mandates that individuals:

Seek medical help right away.
Contact a Poison Control Center or call the local emergency number immediately.

Management and Monitoring

No specific antidote is known for acute estriol overdose. Management is symptomatic and supportive to address the manifested clinical signs. In serious cases, procedural steps may include the monitoring of vital signs and the use of interventions such as activated charcoal or intravenous fluids, as determined by medical professionals.

Therapeutic Uses of Trophicreme

What Trophicreme Treats: Main Uses and Benefits

Trophicreme is generally considered relevant for women in the postmenopausal phase, and is commonly used to address the conditions presenting with systemic or localized discomfort caused by local estrogen deficiency. This therapeutic approach supports the tissue health in the lower urogenital tract, helping to ease the overall symptom burden. This category of local treatment is applied in situations involving atrophic complaints.

The medicine is used for managing symptom clusters related to Vulvovaginal Atrophy (VVA) and the overall Genitourinary Syndrome of Menopause (GSM). The goal of therapy involves supporting the restoration of the vaginal lining, addressing chronic tissue changes, and providing symptomatic relief for pervasive vaginal dryness, persistent burning, and dyspareunia (painful sexual intercourse).

The clinical benefit may be associated with restoring physical comfort. The treatment plays a role in managing symptom patterns that interfere with daily comfort, making it relevant when supportive symptom management is appropriate. This symptomatic relief helps improve day-to-day comfort and supports general well-being.

Quick Fact: Relief for GSM Symptoms
Trophicreme is relevant for easing symptoms related to VVA, chronic dryness, and dyspareunia (painful sexual intercourse). It also assists with managing lower urogenital discomforts, such as urgency or frequency, when these are linked to tissue atrophy.

Regulatory References

Ovestin Cream - Consumer Medicine Information (CMI) summary

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Trophicreme

The eligibility for Trophicreme (Estriol vaginal cream) is determined by regulatory bodies based on specific medical history and physiological status. The medicine is formally approved for postmenopausal women but is strictly excluded for individuals with certain health conditions.

Official Eligibility Statements:

The medicine is contraindicated in any woman with a current or past history of estrogen-dependent malignancy, such as breast cancer, or suspected endometrial cancer.
Use is prohibited in the presence of active thromboembolic disease (blood clots in legs or lungs), severe arterial disease (stroke, heart attack), or known thrombophilic disorders.
Trophicreme is contraindicated for those with acute liver disease, undiagnosed genital bleeding, untreated endometrial hyperplasia, porphyria, or known hypersensitivity to the ingredients.
Use is not indicated for the pediatric population, pregnant individuals, or those who are breastfeeding.

Eligibility-Related Restrictions:

Close medical supervision is required for women with conditions like hypertension, diabetes mellitus, Systemic Lupus Erythematosus (SLE), epilepsy, asthma, or uterine fibroids (leiomyoma).
Geriatric use (women over 65) requires close supervision due to higher baseline risks associated with hormone therapy.

Connection to the overall eligibility profile:

Regulatory documents establish a comprehensive set of contraindications related to cancer, thrombosis, and organ function, which strictly prohibit use across certain populations. Trophicreme is officially permitted for postmenopausal women who are free from these specific absolute contraindications and can be closely monitored for other pre-existing conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Trophicreme’s interaction profile is primarily defined by its local route of administration as a vaginal cream, which results in minimal systemic absorption of its active ingredient, Estriol. Government regulatory documents state that because of this low exposure, the occurrence of clinically relevant drug interactions is unlikely compared to systemic estrogen therapy.

Documented Pharmacokinetic Interactions

Despite the low systemic absorption, Estriol belongs to the estrogen class, which is partially metabolized by the CYP3A4 enzyme system. Therefore, interactions associated with this metabolic pathway are documented as a class effect. Co-administration with known CYP3A4 inducers may theoretically reduce estriol plasma concentrations. Examples of documented inducers include medicines such as rifampin and phenobarbital, as well as the herbal product St. John's Wort.

Conversely, co-administration with strong CYP3A4 inhibitors may theoretically increase plasma concentrations of estriol. Examples of substances classified as inhibitors include certain antifungals like ketoconazole, antivirals like ritonavir, and the food substance Grapefruit Juice.

Restrictions and Limitations

No specific drug-drug combinations are formally listed as contraindicated, and regulatory labels do not mandate any specific timing or separation requirements for this product.

Mechanism of Action

Trophicreme is a selective antagonist that primarily targets the P2Y14 receptor, a G-protein coupled receptor (GPCR) predominantly expressed on the surface of immune cells and osteoclast precursors. This molecular interaction defines the initial biological target. The active compound binds reversibly to the extracellular binding pocket of the P2Y14 receptor, preventing the endogenous ligand from initiating signal transduction.

Binding of Trophicreme to the P2Y14 receptor initiates a cascade that modulates intracellular signaling. Specifically, the receptor antagonism inhibits the Gi protein-mediated reduction of cyclic adenosine monophosphate (cAMP) levels. This maintenance of higher intracellular cAMP concentrations interferes with the downstream activation of the p38 mitogen-activated protein kinase (MAPK) pathway. The subsequent lack of p38 activation modulates the expression of key genes necessary for cell maturation.

This pathway modulation culminates in a system-level physiological consequence within the target tissues. By disrupting p38-dependent gene transcription, Trophicreme suppresses the differentiation of monocytes into mature, bone-resorbing osteoclasts. Furthermore, the antagonistic activity modulates the release profile of specific inflammatory cytokines within the local tissue environment, influencing the paracrine signaling that regulates cellular turnover.

Dosage and Administration Information

Official Administration Guidelines for Trophicreme

Trophicreme is an estriol vaginal cream intended for vaginal administration only. The official instructions for its use detail a precise, phased dosing schedule and specific steps for preparation and application, strictly for adult patients.

Administration Scope	Detail
Route	Vaginal Cream
Initial Dose	1 applicator up to the ring (0.5 mg estriol in 0.5 g of cream) once daily for a maximum of 4 weeks.
Maintenance Dose	1 applicator up to the ring (0.5 mg estriol in 0.5 g of cream) twice a week.
Missed Dose	Apply the missed dose immediately, unless it is more than 12 hours late, in which case the dose must be skipped. Do not apply more than one dose per day.

Procedural Steps

The cream is administered using the supplied applicator. The documented steps begin with removing the cap and piercing the tube seal, followed by screwing the applicator onto the tube. The tube is gently squeezed to fill the applicator barrel precisely to the red ring mark (0.5 g or 1 g dose, depending on the product’s specific dosage). The applicator is then unscrewed, and the cap is replaced on the tube.

For administration, the patient should lie down or stand in a comfortable position and insert the applicator deep into the vagina, gently pushing the plunger completely to dispense the cream. The applicator must be removed while the plunger is depressed. After each use, the applicator must be disassembled by pulling out the plunger and washed with mild soap and warm water (not boiling), rinsed thoroughly, and reassembled for the next application. The standard maintenance regimen is applied twice weekly. Special application schedules, such as daily dosing for 2 weeks before vaginal surgery and a 2-week pause before resuming the twice-weekly dose post-surgery, are utilized.

Recent Clinical Evidence

Trophicreme: Recent Clinical Evidence

This overview is a non-advisory summary of the clinical research conducted on the study of local estriol therapy, as found in regulatory and peer-reviewed scientific sources.

The Core Research: Vulvovaginal Atrophy (VVA) and GSM Symptoms

Research for this type of local therapy has been conducted primarily in the context of Vulvovaginal Atrophy (VVA), which is a key part of the Genitourinary Syndrome of Menopause (GSM). Studies used high-quality Randomized Controlled Trials (RCTs) to examine how patient-reported symptoms—such as vaginal dryness and pain during sexual intercourse (dyspareunia)—change over defined time intervals. Research also examined objective measurements, including the Vaginal Maturation Index (VMI) and the Vaginal Health Index (VHI).

In these short-term trials, studies reported patterns observed in objective markers and changes in patient-reported outcomes. Clinical laboratory studies also explored the systemic absorption profile, and data show patterns related to minimal systemic exposure of the active ingredient following vaginal administration in the studied populations.

Evidence in Specific Patient Groups and Limitations

Research has explored the study of local estriol therapy in special populations, particularly postmenopausal women who are receiving treatment for hormone receptor-positive breast cancer using Aromatase Inhibitors (AIs). For this group, studies monitored circulating levels of hormones, and data show patterns related to minimal systemic exposure of estriol. However, these trials often had modest sample sizes and limited follow-up duration (around 12 weeks).

Regarding long-term effects, the majority of core efficacy trials had follow-up durations limited to a few months. Therefore, long-term effects are not fully established regarding the maintenance of measured outcomes beyond the intermediate-term. Comparative evidence is also lacking in large, head-to-head randomized trials that compare estriol cream against all other available low-dose local estrogen formulations. Research highlights what is known—and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Trophicreme (FAQ)

Q: Is Trophicreme available without a prescription?

No. According to the official classification by major regulatory bodies, Trophicreme is consistently categorized as a prescription-only medicine (POM). The drug's classification indicates it is obtained by prescription.

Q: Can Trophicreme be used on the face?

No. Official administration instructions strictly mandate that Trophicreme is a vaginal cream and is intended for vaginal administration only using the supplied applicator. Official instructions do not include use on the face or other non-specified areas.

Q: Can Trophicreme be used during pregnancy, according to official information?

No. Regulatory documents state that Trophicreme is contraindicated (prohibited) for use during pregnancy. The prohibition is consistent with safety guidance for medicines in its class.

Q: Is Trophicreme a prescription-only medicine in most countries?

Yes. Regulatory bodies across various countries consistently classify Trophicreme as a prescription-only medicine. This classification is used to ensure medical supervision is involved in its use.

Q: What is the difference between Trophicreme and Trophicreme Forte?

The official product information indicates that different formulations, such as those labeled 'Forte,' are distinguished by the strength or concentration of the active ingredient, Estriol. The specific amount of active substance is detailed in the composition sections of regulatory documents.

Q: Are there different strengths of Trophicreme?

Yes. Regulatory documents and official dosage tables confirm that the active ingredient, Estriol, is available in different strengths for vaginal administration. The appropriate strength is determined by the prescribing health professional.

Q: Is it normal to see an initial flare-up of symptoms when starting Trophicreme?

Official safety notes state that local irritation may be more noticeable at the start of treatment compared to later on. This localized irritation may be expected to resolve after the initial weeks of use.

Q: Does Trophicreme cause any kind of burning or stinging feeling?

Regulatory documents list vaginal irritation and localized discomfort as common side effects. These commonly reported localized adverse reactions may be described by users as a burning or stinging feeling.

Q: What are the most commonly reported safety concerns in clinical trials?

The most commonly reported effects listed in regulatory documents are localized adverse reactions. These include vaginal irritation, itching, increased vaginal discharge, as well as headache and breast tenderness.

Q: Are there any known long-term side effects associated with Trophicreme use?

Regulatory summaries note that the majority of efficacy trials had a follow-up duration limited to a few months. Long-term effects are not fully established regarding outcomes beyond the intermediate-term.

Q: Is there a maximum time frame for using Trophicreme?

Regulatory guidance states that therapy should only be continued as long as the benefit outweighs the risk. Official guidance requires the risks and benefits to be medically appraised at least once a year.

Q: Why is Trophicreme sometimes prescribed for long-term use?

Regulatory documents state that continuation of treatment is determined based on an assessment that the benefits of the medication outweigh the potential risks. Official guidance requires this medical appraisal to be performed at least annually.

Q: How quickly does Trophicreme start working?

Regulatory documents indicate that the maintenance dosage is typically reached following a gradual reduction in the initial daily dose, which is determined by the relief of symptoms. This initial phase of daily treatment is usually limited to the first few weeks.

Q: What is the typical duration of treatment described in official guides?

Official guides describe an initial daily dose that is taken for a maximum of 4 weeks. This is then followed by a lower maintenance dosage that is typically administered twice a week.

Q: Are there any common misuses of Trophicreme that people should know about?

Official instructions emphasize the importance of following the precise administration schedule and method for Trophicreme. It is specifically intended for vaginal administration to achieve the correct local effect and limit systemic exposure.

Q: Does Trophicreme cause changes to skin pigmentation?

The active ingredient in this medicine belongs to the estrogen class. Systemic effects associated with this class include the documented possibility of changes in skin color or increased pigmentation (chloasma).

Q: Why do some users report dryness after using Trophicreme?

While the specific symptom of dryness is not always listed, the common adverse reactions noted in regulatory documents include vaginal irritation and itching. These effects may sometimes be associated with a subjective feeling of localized dryness.

Q: Is it normal for Trophicreme to feel greasy?

The medicine is officially manufactured as an aqueous-based cream formulated for mucosal application. This cream consistency is different from gels or other preparations and may be perceived as greasy by some users upon application.

Q: Does Trophicreme contain any parabens or common allergens?

Official composition information lists the active ingredient (Estriol) and the excipients (inactive ingredients). It is necessary to check the full regulatory list, as some excipients may include substances such as parabens or allergens like arachis oil (peanut oil).

Q: Does Trophicreme contain any animal-derived ingredients?

The active ingredient, Estriol, is a naturally occurring, bioidentical human hormone. However, the full list of excipients (inactive ingredients) in the cream base would need to be checked in the official product information, as some components may be derived from animal sources.

Q: Can alcohol consumption interact with Trophicreme?

The cream is not known to interact directly with alcohol due to its low systemic absorption. However, regulatory guidance related to the estrogen class includes information about alcohol's separate association with increased breast cancer risk.

Q: Are there any dietary restrictions mentioned for users of Trophicreme?

Official guidance states that users can generally eat and drink normally. The interaction profile does specifically note Grapefruit Juice as a substance that may theoretically affect plasma concentrations due to its interaction with the CYP3A4 enzyme system.

Q: Is Trophicreme typically used for fungal infections?

No. The official therapeutic indications for Trophicreme (Estriol vaginal cream) are for conditions related to atrophy of the lower urogenital tract and associated symptoms. It is not indicated for the treatment of fungal infections.

Q: What does the research say about Trophicreme's success rate?

Clinical research evidence is summarized by the study of patient-reported outcomes (such as vaginal dryness) and changes in objective markers like the Vaginal Maturation Index. These markers are used to assess the patterns of change during defined treatment intervals.

How should Trophicreme be stored and disposed of?

The official storage and disposal instructions for Trophicreme (Estriol Vaginal Cream) must be followed to maintain product stability and ensure proper environmental handling.

Storage Requirements

The medicine must be stored at a temperature below 25 C (77 F) and must not be frozen. It is required to be kept in the original container/outer carton and protected from light and moisture. After initial use, the tube must be kept tightly closed, and the product should be used within the specific in-use stability period, which is often three months.

Disposal Instructions

All unused or expired medicine, including the tube and applicator, must not be disposed of in household waste or wastewater. The product must be returned to an authorized pharmacy or local drug take-back program for safe pharmaceutical waste disposal, according to local regulations. Like all medicines, Trophicreme must be kept out of the sight and reach of children.

Trophicreme